Archive for the ‘Wiki’ Category


Ibogaine – Binding profile

Ibogaine has affinity (Ki) for the following sites in decreasing order of potency: σ2 (206 nM) > SERT (548.7 nM) > DAT (1,980 nM) > NMDA (2,001 nM) > κ-opioid (2,717 nM) > µ-opioid (4,362 nM) > σ1 (5,839 nM) > M3 (12,500 nM) > 5-HT2A (14,142 nM) > M1 (22,486 nM) > M2 (39,409 [...]

Read More...

Ibogaine – Metabolites

Ibogaine is metabolized in the human body by cytochrome P450 2D6, and the major metabolite is noribogaine (12-hydroxyibogamine). Noribogaine is most potent as a serotonin reuptake inhibitor and acts as a moderate κ- and weak µ-opioid receptor full agonist and therefore, also has an aspect of an opiate replacement similar to compounds like methadone. It [...]

Read More...

Ibogaine – Pharmacology

The pharmacology of ibogaine is quite complex, affecting many different neurotransmitter systems simultaneously.Because of its fairly low potency at any of its target sites, ibogaine is used in doses anywhere from 5 mg/kg of body weight for a minor effect to 30 mg/kg in the cases of strong polysubstance addiction. It is unknown whether doses greater than [...]

Read More...

Ibogaine – In popular culture

Ibogaine first appeared in popular culture in the writings of Hunter S. Thompson. While covering the Wisconsin primaries of the 1972 U.S. Presidential primaries for Rolling Stone magazine, Thompson claimed that presidential candidate Edmund Muskie showed symptoms of being under the influence of Ibogaine. This assertion was later revealed by Thompson to be false, one [...]

Read More...

Ibogaine – Research

An ibogaine research project was funded by the US National Institute on Drug Abuse in the early 1990s. The National Institute on Drug Abuse (NIDA) abandoned efforts to continue this project into clinical studies in 1995, citing other reports that suggested a risk of brain damage with extremely high doses and fatal heart arrhythmia in [...]

Read More...